Cargando…

Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients

BACKGROUND: Drug-metabolizing enzymes play a role in chemical carcinogenesis through enzymatic activation of procarcinogens to biologically reactive metabolites. The role of gene polymorphisms of several cytochrome P450 enzymes in digestive cancer risk has been extensively investigated. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gervasini, Guillermo, García-Martín, Elena, Ladero, José M, Pizarro, Rosa, Sastre, Javier, Martínez, Carmen, García, Monserrat, Diaz-Rubio, Manuel, Agúndez, José AG
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931602/ https://www.ncbi.nlm.nih.gov/pubmed/17605821 http://dx.doi.org/10.1186/1471-2407-7-118

Ejemplares similares

Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk
por: Ladero, José M., et al.
Publicado: (2012)

Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy
por: Martínez, C, et al.
Publicado: (2002)

Influence of Vitamin D-Related Gene Polymorphisms (CYP27B and VDR) on the Response to Interferon/Ribavirin Therapy in Chronic Hepatitis C
por: García-Martín, Elena, et al.
Publicado: (2013)

Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b(5)
por: Gómez-Tabales, Javier, et al.
Publicado: (2020)

Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk
por: Bethke, Lara, et al.
Publicado: (2007)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

CYP3A4 and CYP3A5 genotyping by Pyrosequencing
por: Garsa, Adam A, et al.
Publicado: (2005)

CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study
por: San Jose, Carmen, et al.
Publicado: (2010)

Goniodysgenesis variability and activity of CYP1B1 genotypes in primary congenital glaucoma
por: García-Antón, María T., et al.
Publicado: (2017)

MD Investigation on the Interaction between Carbamazepine and Two CYP Isoforms, CYP3A4 and CYP3A5
por: Liu, Shuhui, et al.
Publicado: (2023)

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
por: Denisenko, Natalia P, et al.
Publicado: (2018)

Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity
por: Rodríguez-Morató, Jose, et al.
Publicado: (2019)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2020)

Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes
por: Lee, Jin Sol, et al.
Publicado: (2013)

Effects of Ninjin'yoeito on Human CYP3A and Mouse CYP3A Activity
por: Kaneda, Marisa, et al.
Publicado: (2023)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Genetic variability of histamine receptors in patients with Parkinson's disease
por: García-Martín, Elena, et al.
Publicado: (2008)

Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia-inducible factor 1α-mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation
por: Valencia-Cervantes, Jesús, et al.
Publicado: (2019)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs
por: Macías, Yolanda, et al.
Publicado: (2021)

Frequency of CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism in a Spanish Population: Linkage Disequilibrium with CYP2C9*3 Allele
por: Dorado, Pedro, et al.
Publicado: (2022)

Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

CYP1B1 mutations in Spanish patients with primary congenital glaucoma: phenotypic and functional variability
por: Campos-Mollo, Ezequiel, et al.
Publicado: (2009)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

MicroRNA regulation of CYP 1A2, CYP3A4 and CYP2E1 expression in acetaminophen toxicity
por: Gill, Pritmohinder, et al.
Publicado: (2017)

Comparison of Paeoniflorin and Albiflorin on Human CYP3A4 and CYP2D6
por: Gao, Li-Na, et al.
Publicado: (2015)

Genomic Structure of the Porcine CYP19 Locus and Expression of the CYP19A3 Paralog
por: Vanselow, Jens, et al.
Publicado: (2021)

CYP2C8 *3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride
por: Campodónico, Diana María, et al.
Publicado: (2022)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2016)

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor
por: Li, Xiaoyan, et al.
Publicado: (2022)

CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
por: Schmidt, R, et al.
Publicado: (2004)

A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, and VKORC1 Genes
por: Tron, Camille, et al.
Publicado: (2022)

Biological interactions of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation recipients
por: Chiu, King-Wah, et al.
Publicado: (2013)

Association of CYP3A5(*)3, CYP3A4(*)18 & CYP2B6(*)6 polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
por: Asadov, Chingiz, et al.
Publicado: (2023)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hcjsmsccfec44n2kehudcghquc